Glioma is the most common primary intraparenchymal tumor of the brain and the 5-year
survival rate of high-grade glioma is poor. Magnetic resonance imaging (MRI) is essential for …

AbstractThe T2-FLAIR (fluid attenuated inversion recovery) mismatch sign is an easily
detectable imaging sign on routine clinical MRI studies that suggests diagnosis of isocitrate …

Background Diagnostic classification of diffuse gliomas now requires an assessment of
molecular features, often including IDH-mutation and 1p19q-codeletion status. Because …

Objectives To evaluate the diagnostic performance of the T2-FLAIR mismatch sign for
prediction of isocitrate dehydrogenase (IDH)-mutant, 1p/19q-noncodeleted lower-grade …

Background Molecular characterization plays a crucial role in glioma classification which
impacts treatment strategy and patient outcome. Dynamic susceptibility contrast (DSC) and …

T2-FLAIR mismatch sign is known as a highly specific imaging marker of IDH-mutant
astrocytomas. This study was intended to clarify what the T2-FLAIR mismatch sign …

Background Accurate and noninvasive detection of isocitrate dehydrogenase (IDH,
including IDH1 and IDH2) status is clinically meaningful for molecular stratification of glioma …

Abstract Background The T2-FLAIR mismatch sign is an imaging finding highly suggestive of
isocitrate dehydrogenase mutated (IDH-mut) 1p19q non-codeleted (non-codel) gliomas …

Purpose of Review IDH-mutant low-grade gliomas (LGG) have emerged as a distinct clinical
and molecular entity with unique treatment considerations. Here, we review updates in IDH …

Simple Summary Advanced neuroimaging is gaining increasing relevance for the
characterization and the molecular profiling of brain tumor tissue. On one hand, for some …